Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05198349 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of M1069 in Advanced Solid Tumors
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05198349 is a Phase 1 study that was terminated before completion, run by EMD Serono Research & Development Institute. The registered enrollment target is 15 participants.
The verdict
NCT05198349, a Phase 1 study, was terminated before completion, sponsored by EMD Serono Research & Development Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.
Interventions
- DRUG M1069
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2023-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05198349
The ClinicalTrials.gov registry entry for NCT05198349 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which M1069 is the first listed.
NCT05198349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05198349 about?
NCT05198349 is a clinical study titled "First in Human Study of M1069 in Advanced Solid Tumors". The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.
What is the current status of trial NCT05198349?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-03-02. Estimated completion is 2023-08-10.
What interventions are being tested in trial NCT05198349?
The interventions under investigation include: M1069 (DRUG).
Who is sponsoring clinical trial NCT05198349?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.